Compassionate use of Quantum Magnetic Resonance Therapy for treatment of children with Diffuse Brainstem Glioma in Mexico City: a single institutional experience

• Published in: Journal of neuro-oncology Vol. 157; no. 2; pp. 377 - 382
• Main Authors: Barragán-Pérez, Eduardo Javier, Alvarez-Amado, Daniel Eduardo, Dies-Suarez, Pilar, Tobón, Silvia Hidalgo, García-Beristain, Juan Carlos, Peñaloza-González, José Gabriel
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.04.2022; Springer Nature B.V
• Subjects: Brain cancer; Brain stem; Brain Stem Neoplasms - diagnostic imaging; Brain Stem Neoplasms - radiotherapy; Brain tumors; Child; Children; Clinical Study; Compassionate Use Trials; Glioma; Glioma - drug therapy; Glioma - therapy; Humans; Magnetic Fields; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Medical prognosis; Medicine; Medicine & Public Health; Mexico; NCT; NCT03577600; Neuroimaging; Neurology; Oncology; Patients; Statistical analysis; Survival; Survival analysis; Mexico; Magnetic field therapy; Brainstem tumors; Quantum magnetic resonance therapy; Diffuse midline glioma; Pediatric brain tumor; Diffuse intrinsic pontine glioma
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-022-03972-2

Purpose Diffuse Brainstem Glioma (DBG) is a catastrophic brain tumor with a survival rate of less than 10% two years after diagnosis despite the existence of different treatment protocols. Among the devices that use magnetic fields generated by Magnetic Resonance Imaging is Quantum Magnetic Resonance Therapy (QMRT). Methods Five children diagnosed with DBG in our institution in Mexico City underwent treatment of compassionate use with QMRT between December 2018 and July 2019. A survival analysis was performed with previously reported historical data (n = 15). Results Two patients (40%) survived after three years of follow-up; the log-rank test showed a statistically significant difference in overall survival between both groups ( p  = 0.032). All patients tolerated the treatment adequately without reporting any severe clinical or neuroradiological adverse effects. Of the patients included, all showed a decrease in the tumor one month after the end of the treatment, although there was great variability in the response and the difference was not statistically significant ( p  = 0.06). Conclusions Although future investigations are needed to confirm the findings reported in the present study, the improvement in survival is promising for a group of patients whose prognosis has been catastrophic over the years. Trial registration NCT03577600.